Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25614656 | 0.97 | ALDH1A1 (0.33) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL25614812 | 0.92 | PRKDC (0.31) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL24622685 | 0.91 | NPC1 (0.32) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL25614844 | 0.91 | ALDH1A1 (0.33) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL24622643 | 0.91 | NPC1 (0.32) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL25614658 | 0.91 | ALDH1A1 (0.34) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL25614728 | 0.89 | HCRTR1 (0.30) | HCRTR1NPC1RAB9AMMP12MMP13 | |
| SCHEMBL25614612 | 0.89 | HCRTR1 (0.30) | HCRTR1NPC1RAB9AMMP12MMP13 | |
| SCHEMBL25614785 | 0.88 | KDM4E (0.32) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL25614680 | 0.88 | ALDH1A1 (0.32) | MEN1KMT2AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | OR51E2, SQLE, ODC1 | MEN1 1387/4885KMT2A 3429/4885KDM4E 3224/4885 |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | LEF1, OCIAD1, OR10J3 | MEN1 964/4885KMT2A 1598/4885KDM4E 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.